Analysis: Positioning to Benefit within Addus HomeCare, Adamas Pharmaceuticals, ManTech International, Yintech Investment, GRIDSUM HOLDING, and Blucora — Research Highlights Growth, Revenue, and Conso

Analysis: Positioning to Benefit within Addus HomeCare, Adamas Pharmaceuticals, ManTech International, Yintech Investment, GRIDSUM HOLDING, and Blucora — Research Highlights Growth, Revenue, and Consolidated Results

NEW YORK, April 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Addus HomeCare Corporation (NASDAQ:ADUS), Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), ManTech International Corporation (NASDAQ:MANT), Yintech Investment Holdings Limited (NASDAQ:YIN), GRIDSUM HOLDING (NASDAQ:GSUM), and Blucora, Inc. (NASDAQ:BCOR), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

ADUS DOWNLOAD: http://Fundamental-Markets.com/register/?so=ADUS
ADMS DOWNLOAD: http://Fundamental-Markets.com/register/?so=ADMS
MANT DOWNLOAD: http://Fundamental-Markets.com/register/?so=MANT
YIN DOWNLOAD: http://Fundamental-Markets.com/register/?so=YIN
GSUM DOWNLOAD: http://Fundamental-Markets.com/register/?so=GSUM
BCOR DOWNLOAD: http://Fundamental-Markets.com/register/?so=BCOR

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Addus HomeCare Corporation (NASDAQ:ADUS), Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), ManTech International Corporation (NASDAQ:MANT), Yintech Investment Holdings Limited (NASDAQ:YIN), GRIDSUM HOLDING (NASDAQ:GSUM), and Blucora, Inc. (NASDAQ:BCOR) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed April 11th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

ADDUS HOMECARE CORPORATION (ADUS) REPORT OVERVIEW

Addus HomeCare's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Addus HomeCare reported revenue of $111.96MM vs $103.66MM (up 8.01%) and basic earnings per share $0.28 vs $0.67 (down 58.21%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Addus HomeCare reported revenue of $425.72MM vs $400.69MM (up 6.25%) and basic earnings per share $1.19 vs $1.06 (up 12.26%). Addus HomeCare is expected to report earnings on May 14th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.32.

To read the full Addus HomeCare Corporation (ADUS) report, download it here: http://Fundamental-Markets.com/register/?so=ADUS

-----------------------------------------

ADAMAS PHARMACEUTICALS, INC. (ADMS) REPORT OVERVIEW

Adamas Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Adamas Pharmaceuticals reported revenue of $0.57MM vs $0.04MM (up 1,435.14%) and basic earnings per share -$1.28 vs -$0.68. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Adamas Pharmaceuticals reported revenue of $0.57MM vs $0.57MM (down 0.17%) and basic earnings per share -$3.97 vs -$2.77. Adamas Pharmaceuticals is expected to report earnings on May 8th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.72. The estimated EPS forecast for the next fiscal year is -$3.91 and is expected to report on February 28th, 2019.

To read the full Adamas Pharmaceuticals, Inc. (ADMS) report, download it here: http://Fundamental-Markets.com/register/?so=ADMS

-----------------------------------------

MANTECH INTERNATIONAL CORPORATION (MANT) REPORT OVERVIEW

ManTech International's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, ManTech International reported revenue of $462.28MM vs $394.18MM (up 17.28%) and basic earnings per share $1.76 vs $0.36 (up 388.89%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, ManTech International reported revenue of $1,717.02MM vs $1,601.60MM (up 7.21%) and basic earnings per share $2.94 vs $1.48 (up 98.65%). ManTech International is expected to report earnings on May 2nd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.39. The estimated EPS forecast for the next fiscal year is $2.18 and is expected to report on February 20th, 2019.

To read the full ManTech International Corporation (MANT) report, download it here: http://Fundamental-Markets.com/register/?so=MANT

-----------------------------------------

YINTECH INVESTMENT HOLDINGS LIMITED (YIN) REPORT OVERVIEW

Yintech Investment's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Yintech Investment reported revenue of $58.21MM vs $112.13MM (down 48.08%) and basic earnings per share $0.14 vs $0.60 (down 76.14%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Yintech Investment reported revenue of $362.44MM vs $391.70MM (down 7.47%) and basic earnings per share $1.02 vs $2.20 (down 53.64%). Yintech Investment is expected to report earnings on May 22nd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.77. The estimated EPS forecast for the next fiscal year is $1.83 and is expected to report on March 12th, 2019.

To read the full Yintech Investment Holdings Limited (YIN) report, download it here: http://Fundamental-Markets.com/register/?so=YIN

-----------------------------------------

GRIDSUM HOLDING (GSUM) REPORT OVERVIEW

GRIDSUM HOLDING's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, GRIDSUM HOLDING reported revenue of $22.76MM vs $14.80MM (up 53.76%) and basic earnings per share -$0.17 vs -$0.35. For the twelve months ended December 31st, 2016 vs December 31st, 2015, GRIDSUM HOLDING reported revenue of $57.65MM vs $35.34MM (up 63.15%) and basic earnings per share -$0.93 vs -$1.28. GRIDSUM HOLDING is expected to report earnings on May 24th, 2018. The report will be for the fiscal period ending March 31st, 2018.

To read the full GRIDSUM HOLDING (GSUM) report, download it here: http://Fundamental-Markets.com/register/?so=GSUM

-----------------------------------------

BLUCORA, INC. (BCOR) REPORT OVERVIEW

Blucora's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Blucora reported revenue of $97.85MM vs $86.80MM (up 12.73%) and basic earnings per share $0.17 vs -$0.47. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Blucora reported revenue of $509.56MM vs $455.91MM (up 11.77%) and basic earnings per share $0.61 vs -$1.57. Blucora is expected to report earnings on May 3rd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $1.00. The estimated EPS forecast for the next fiscal year is $1.86 and is expected to report on February 21st, 2019.

To read the full Blucora, Inc. (BCOR) report, download it here: http://Fundamental-Markets.com/register/?so=BCOR

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.